CD40 blockade hampers IgG class-switch while enhancing Granzyme B production by transitional B cells

CD40-CD40L interaction is crucial for the interplay between B and T cells and determines B-cell fate. Here, we investigated the effects of CD40-CD40L inhibition on B-cell subsets and cytokine production using the non-depleting monoclonal anti-CD40 antibody CFZ534. CFZ534 had no impact on B-cell viability but inhibited TLR9-agonistic (CpG-ODN) CD40L- as well as CD40L-mediated proliferation. The plasmablast subset was reduced after stimulation with CpG-ODN + CD40L, but this effect was completely restored by CFZ534-mediated CD40 blockade. IgG as well as IgM-secreting cells were significantly reduced in the presence of CFZ534 upon CD40L stimulation. CpG-ODN, but not CD40L, induced Granzyme B production in B cells after CD40-blockade and CpG-ODN/CD40L stimulation. Moreover, we found that IL-10 and Granzyme B were produced by separate B-cell subsets. Hence, CD40-blockade mediated by CFZ534 increased Granzyme B production and decreased IL-10 production in CD24hiCD38hi B cells with a transitional phenotype and led to a significant decrease in the expression of the pro-inflammatory cytokines IL-6, IL-12p35, and IL-23p19 and TNFα in a B and CD4 + TH-cell co-culture system. Based on these preclinical results, CD40 blockade by the Fc-silent, non-depleting monoclonal antibody CFZ534 exerts an anti-inflammatory effect on B cells, including hampering the IgG class switch without affecting their viability.

Authors

Institutions

Publication Details

Journal
Clinical & Experimental Immunology
Published
2025-01-01
DOI
https://doi.org/10.1093/cei/uxaf044
Citations
1
Primary Topic
T-cell and B-cell Immunology
Type
article
Field-Weighted Citation Impact
0.80
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

CD40 blockade hampers IgG class-switch while enhancing Granzyme B production by transitional B cells

Catherine H. Régnier, Felix Werner, Ida Allabauer, Wolfgang Schuh et al.
1 citations
Clinical & Experimental Immunology
T-cell and B-cell Immunology
0.80
article

CD40 blockade hampers IgG class-switch while enhancing Granzyme B production by transitional B cells

Catherine H. Régnier, Felix Werner, Ida Allabauer, Wolfgang Schuh, Mandy Wahlbuhl, B. Dietel-Schor, Alexander Schnell, Holger Hackstein, James S. Rush, Hans‐Martin Jäck, Christian H.K. Lehmann, Adrian Hoffmann, Jens Wittner, André Hoerning, Joachim Woelfle, Tobias Krickau
article en
1 citations

Abstract

CD40-CD40L interaction is crucial for the interplay between B and T cells and determines B-cell fate. Here, we investigated the effects of CD40-CD40L inhibition on B-cell subsets and cytokine production using the non-depleting monoclonal anti-CD40 antibody CFZ534. CFZ534 had no impact on B-cell viability but inhibited TLR9-agonistic (CpG-ODN) CD40L- as well as CD40L-mediated proliferation. The plasmablast subset was reduced after stimulation with CpG-ODN + CD40L, but this effect was completely restored by CFZ534-mediated CD40 blockade. IgG as well as IgM-secreting cells were significantly reduced in the presence of CFZ534 upon CD40L stimulation. CpG-ODN, but not CD40L, induced Granzyme B production in B cells after CD40-blockade and CpG-ODN/CD40L stimulation. Moreover, we found that IL-10 and Granzyme B were produced by separate B-cell subsets. Hence, CD40-blockade mediated by CFZ534 increased Granzyme B production and decreased IL-10 production in CD24hiCD38hi B cells with a transitional phenotype and led to a significant decrease in the expression of the pro-inflammatory cytokines IL-6, IL-12p35, and IL-23p19 and TNFα in a B and CD4 + TH-cell co-culture system. Based on these preclinical results, CD40 blockade by the Fc-silent, non-depleting monoclonal antibody CFZ534 exerts an anti-inflammatory effect on B cells, including hampering the IgG class switch without affecting their viability.

Clinical & Experimental ImmunologyVol. 219(1)
Novartis (Switzerland) (CH), Friedrich-Alexander-Universität Erlangen-Nürnberg (DE), University Medical Center Freiburg (DE), Universitätsklinikum Erlangen (DE), Integrated BioTherapeutics (United States) (US), Comprehensive Cancer Center Erlangen (DE)
Openalex Percentile: Top 25%
T-cell and B-cell Immunology
0.80
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.